Study to Evaluate Made-to-measure Compression Garments

Inclusion Criteria: 1. Signed Informed Consent Form 2. Men, women or diverse aged 18 years or up to 70 years with full legal competence 3. Patient is mentally and physically able to participate in the study 4. Capability to understand the subject information and to provide conscious informed consent 5. Capability and willingness to follow protocol requirements 6. All female or diverse subjects of childbearing potential must agree to use a reliable method of contraception with a Pearl-Index of less than 1% per year when used consistently and correctly\* (\*such as hormone implants,injectables, combined oral contraceptives (combined gestagen-estrogen pills), some intra uterine devices (IUDs), surgically sterility (hysterectomy or tubal ligation), sexual abstinence or vasectomized partner for at least 4 weeks) 7. Mild to moderate lymphedema of the lower and/or upper extremities (ISL stage I or II) 8. Indication and possibility of treatment with a flat-knitted compression garment during the day 9. Patients who are familiar with wearing compression garments 10. Indicated Complete Decongestive Therapy Phase II (Maintenance phase) 11. Willingness to wear the study product at least 5 days a week for at least 6 hours a day Exclusion Criteria: 1. Pregnant or lactating women or diverse subjects 2. Alcohol abuse (mentioned by the patient and/or suspected by the investigator) 3. Drug abuse (mentioned by the patient and/or suspected by the investigator) 4. Patients who need a different compression class (higher or lower than CCL 2) 5. Pronounced skin folds 6. Pronounced shape distortions 7. cG (lymphatic measure of the thigh) \>90 cm for AG stocking 8. Indicated Complete Decongestive Therapy Phase I 9. Known allergy or intolerance to one or more components of the product 10. Advanced arterial insufficiency including ischemia 11. Uncontrolled congestive heart failure 12. Untreated septic phlebitis 13. Phlegmasia coerulea dolens 14. Immobility (confinement to bed). 15. Conditions in which increased venous and lymphatic return is not desired. 16. Weeping dermatosis 17. Cutaneous infections 18. Severely compromised skin sensibility and impaired sensitivity of the limb 19. Advanced peripheral neuropathy 20. Rheumatoid arthritis 21. Complex regional pain syndrome (CRPS, M. Sudeck) 22. Malignant lymphedema 23. Gangrene 24. Sponsors or manufacturers staff 25. Open wounds in the test area 26. Diuretics, except low doses for treatment of hypertension (≤ 12.5 mg Hydrochlorothiazide) 27. Nephrotic syndrome